Skip to main content
AQST
NASDAQ Life Sciences

Aquestive 10-Q: Cash Falls to $90.3M, Stockholders' Deficit Widens to $70.8M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$3.8
Mkt Cap
$486.985M
52W Low
$2.93
52W High
$6.85
52W Position info
30% above low
Off High info
45% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

AQST sits 30% above its 52-week low of $2.93.

Summary

Aquestive's Q3 10-Q confirms the $7.6M revenue and $16.5M net loss already reported, with cash down to $90.3M and stockholders' deficit widening to $70.8M ahead of the March 16, 2027 Anaphylm PDUFA date.


Key Events · Earnings and Guidance · AQST

  • Q3 Revenue Falls 41% to $7.6M

    Total revenues were $7.6M versus $12.8M a year earlier, driven by Suboxone order timing; manufacture and supply revenue fell to $6.7M from $11.5M. Nine-month revenue still rose 14% to $35.8M.

  • Cash Down to $90.3M

    Cash and equivalents fell from $121.2M at December 31, 2025 to $90.3M at September 30, 2026, after $31.3M of operating cash burn; management says funding covers at least the next twelve months.

  • Stockholders' Deficit Widens to $70.8M

    Accumulated deficit reached $494.4M and total stockholders' deficit grew to $(70.8)M from $(33.7)M at year-end, with $55.0M of Oaktree term debt outstanding and $51.9M of royalty obligations.

  • Anaphylm PDUFA Set for March 16, 2027

    The FDA accepted the Anaphylm NDA resubmission as a Class 2 response with a March 16, 2027 goal date; Health Canada submission is expected in Q4 2026 and an EU filing in Q1 2027.


Analysis · AQST · Life Sciences

The headline numbers match this morning's 8-K — Q3 revenue of $7.6M, down 41%, and a $16.5M net loss — but the full quarterly report is where the balance-sheet story sits. Cash dropped to $90.3M from $121.2M at year-end while the company burned $31.3M in operations over nine months, and total stockholders' deficit deepened to $70.8M from $33.7M. Management still says existing cash plus the ATM and expense cuts fund at least twelve months, but the runway now depends on the Anaphylm PDUFA date of March 16, 2027 and on the $55M Oaktree term loan's covenants. Two new 10b5-1 selling plans (Chief People Officer Peter Boyd for up to 200,000 shares, Director Julie Krop for up to 105,000) add to the distribution signal from insider sales already logged in the last 90 days.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AQST was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $487M. The 52-week trading range was $2.93 to $6.85. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AQST - Latest Insights

AQST
Nov 05, 2026, 4:17 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.66
Real-time Price: $3.79 info
Change: +$0.130 (+4%) info
Market Cap: $475.1M info
AQST
Nov 03, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.69
Real-time Price: $3.79 info
Change: +$0.100 (+3%) info
Market Cap: $475.1M info
AQST
Nov 03, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.61
Real-time Price: $3.79 info
Change: +$0.1799 (+5%) info
Market Cap: $475.1M info
AQST
Oct 15, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.58
Real-time Price: $3.79 info
Change: -$0.790 (-17%) info
Market Cap: $475.1M info
AQST
Oct 14, 2026, 7:21 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.79
Real-time Price: $3.79 info
Change: -$1.00 (-21%) info
Market Cap: $475.1M info